Usmarapride

Pharmaceutical compound From Wikipedia, the free encyclopedia

Usmarapride (INNTooltip International Nonproprietary Name; developmental code name SUVN-D4010) is a serotonin 5-HT4 receptor agonist which is or was under development for the treatment of cognitive deficits in Alzheimer's disease and schizophrenia.[1][2][3] It is taken orally.[1]

Other namesSUVN-D4010; SUVN-D-4010
Routes of
administrationOral[1]
Drug classSerotonin 5-HT4 receptor agonist
ATC code
  • None
Quick facts Clinical data, Other names ...
Usmarapride
Clinical data
Other namesSUVN-D4010; SUVN-D-4010
Routes of
administration		Oral[1]
Drug classSerotonin 5-HT4 receptor agonist
ATC code
  • None
Identifiers
  • 2-[1-(3-methoxypropyl)piperidin-4-yl]-5-(1-propan-2-ylindazol-3-yl)-1,3,4-oxadiazole
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H29N5O2
Molar mass383.496 g·mol−1
3D model (JSmol)
  • CC(C)N1C2=CC=CC=C2C(=N1)C3=NN=C(O3)C4CCN(CC4)CCCOC
  • InChI=1S/C21H29N5O2/c1-15(2)26-18-8-5-4-7-17(18)19(24-26)21-23-22-20(28-21)16-9-12-25(13-10-16)11-6-14-27-3/h4-5,7-8,15-16H,6,9-14H2,1-3H3
  • Key:DWTFBJGTRBMHPG-UHFFFAOYSA-N
Close

Pharmacology

The drug is a potent and selective partial agonist of the serotonin 5-HT4 receptor.[2][3] It is highly selective against the serotonin 5-HT3 receptor and other closely related receptors.[2] The drug shows cognition- and memory-enhancing effects, neuroprotective effects, and antidepressant-like effects in preclinical research.[2][3][4] Its pharmacokinetics and pharmacodynamics have been evaluated in humans.[2][5] In terms of chemical structure, the drug is an indazole derivative.[6]

Development

Usmarapride is under development by Suven Life Sciences.[1] As of September 2023, no recent development has been reported for treatment of Alzheimer's disease and schizophrenia.[1] The drug has reached phase 1 clinical trials for both of these indications.[1]

References

Related Articles

Wikiwand AI